Treatment of TRAIL-resistant tumor cells with soluble TRAIL or agonistic αDR5-antibodies could promote tumor survival/proliferation [306,313], invasion and metastases [314,315,316,317], and cytokine production [126,316,318,319,320,321]. The gene discussed is TNFSF10; the disease is neoplasm.